NeuroThera provides a clinical‑grade transcranial photobiomodulation (tPBM) platform that uses near‑infrared laser light to non‑invasively stimulate targeted brain regions, activating mitochondrial function and improving cerebral blood flow. The single device is configurable for major depressive disorder, Alzheimer’s, Parkinson’s, traumatic brain injury, and post‑stroke rehabilitation, offering a drug‑free, portable treatment option for neurologists, psychiatrists, and rehabilitation specialists.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of individuals suffer from major depressive disorder, Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, and stroke, yet existing therapies are limited to symptom management, have significant side effects, or are unavailable, leading to substantial economic and personal burdens.
Solution
NeuroThera offers a clinical‑grade transcranial photobiomodulation (tPBM) platform that delivers near‑infrared laser light to specific brain regions. The light penetrates the scalp and skull, activates mitochondrial cytochrome c oxidase, and enhances cerebral blood flow, metabolism, and cortical activity. This non‑invasive neuromodulation approach is applied across five neurological indications using a single device architecture, reducing development costs and enabling rapid deployment. Clinical trials have shown dose‑dependent biomarker changes with no serious adverse events, providing a safe alternative to systemic drugs. The system is portable and clinic‑ready, allowing treatment in various care settings.
Target Audience
Primary customers are neurologists, psychiatrists, rehabilitation specialists, and healthcare systems seeking non‑pharmacologic, evidence‑based therapies for the listed neurological conditions.
Features
- Near‑infrared laser headset designed for precise photon delivery through scalp and skull to targeted cortical areas
- Mitochondrial activation mechanism that boosts ATP production and reduces oxidative stress in neurons
- Real‑time monitoring of cerebral blood flow and metabolic changes validated by BOLD fMRI, FDG‑PET, and EEG
- Configurable protocols for major depressive disorder, Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, and post‑stroke rehabilitation
- Portable, clinic‑ready form factor enabling treatment in outpatient, inpatient, and tele‑health environments
- Zero systemic side effects and no drug‑drug interactions, eliminating the need for titration or polypharmacy